Literature DB >> 22520128

Five-year cohort study on the burden of hospitalisation for acute diarrhoeal disease in African HIV-infected and HIV-uninfected children: potential benefits of rotavirus vaccine.

Michelle J Groome1, Shabir A Madhi.   

Abstract

INTRODUCTION: Diarrhoea remains an important cause of death in children under five years of age, including in areas with high prevalence of HIV infection. Rotavirus contributes significantly to childhood diarrhoea in South Africa but data on the burden of rotavirus disease in HIV-infected children are limited.
METHODS: This secondary data analysis, involving a cohort of 39,879 children enrolled into a pneumococcal conjugate vaccine efficacy trial, evaluated the incidence of hospitalisation for acute gastroenteritis in HIV-infected and HIV-uninfected children under five years of age from Soweto, South Africa. The data were used to evaluate the potential burden of hospitalisation that would be preventable with rotavirus vaccine.
RESULTS: Acute gastroenteritis (AGE) was identified as a leading cause of hospitalisation in the cohort and was associated with 21% of all hospitalisations. Twenty-six percent of the AGE hospitalisations occurred in HIV-infected children. The incidence of AGE was greatest in the under-6 months age group and 90% of cases occurred within the first two years of life. The overall incidence of AGE was 5.4 fold (CI(95%) 4.9, 6.0) higher in HIV-infected compared to HIV-uninfected children. In addition, the estimates of rotavirus incidence were 2.3 fold (CI(95%) 1.8, 2.9) higher in HIV-infected compared to HIV-uninfected children. HIV-infected children were 1.8 fold (CI(95%) 1.4, 2.4) more likely to have prolonged hospitalisation and the case fatality rate was 4.0 (CI(95%) 2.0, 7.8) fold higher in HIV-infected compared to HIV-uninfected children.
CONCLUSION: Despite rotavirus reportedly being less frequently identified in hospitalised HIV-infected children, the absolute burden of rotavirus-associated hospitalisation is likely to be greater compared to HIV-uninfected children. The introduction of rotavirus vaccine into the national immunisation program in South Africa is likely to benefit HIV-infected and HIV-uninfected children and reduce the overall burden of AGE hospitalisation in our childhood population.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22520128     DOI: 10.1016/j.vaccine.2011.08.004

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

Review 1.  Contribution of Maternal Immunity to Decreased Rotavirus Vaccine Performance in Low- and Middle-Income Countries.

Authors:  Katayi Mwila; Roma Chilengi; Michelo Simuyandi; Sallie R Permar; Sylvia Becker-Dreps
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

2.  Maternal Antiretroviral Therapy Is Associated with Lower Risk of Diarrhea in Early Childhood.

Authors:  Kevin A Sztam; Enju Liu; Karim P Manji; Roland Kupka; Rodrick Kisenge; Said Aboud; Wafaie W Fawzi; Ronald J Bosch; Christopher P Duggan
Journal:  J Pediatr       Date:  2016-05-28       Impact factor: 4.406

3.  Risk Factors for Acute Gastroenteritis Among Patients Hospitalized in 5 Veterans Affairs Medical Centers, 2016-2019.

Authors:  Neha Balachandran; Jordan Cates; Anita K Kambhampati; Vincent C Marconi; Alexis Whitmire; Elena Morales; Sheldon T Brown; Diki Lama; Maria C Rodriguez-Barradas; Rosalba Gomez Moronez; Gilberto Rivera Domiguez; David O Beenhouwer; Aleksandra Poteshkina; Zlatko Anthony Matolek; Mark Holodniy; Cynthia Lucero-Obusan; Madhuri Agarwal; Cristina Cardemil; Umesh Parashar; Sara A Mirza
Journal:  Open Forum Infect Dis       Date:  2022-07-25       Impact factor: 4.423

4.  Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa.

Authors:  Myron J Levin; Jane C Lindsey; Susan S Kaplan; Werner Schimana; Jody Lawrence; Monica M McNeal; Mutsa Bwakura-Dangarembizi; Anthony Ogwu; Evans M Mpabalwani; Paul Sato; George Siberry; Margaret Nelson; Darcy Hille; Geoffrey A Weinberg; Adriana Weinberg
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

Review 5.  Understanding the contribution of common childhood illnesses and opportunistic infections to morbidity and mortality in children living with HIV in resource-limited settings.

Authors:  Surbhi Modi; Alex Chiu; Bernadette Ng'eno; Scott E Kellerman; Nandita Sugandhi; Lulu Muhe
Journal:  AIDS       Date:  2013-11       Impact factor: 4.177

6.  Use of population-based surveillance to determine the incidence of rotavirus gastroenteritis in an urban slum and a rural setting in Kenya.

Authors:  Robert F Breiman; Leonard Cosmas; Allan Audi; William Mwiti; Henry Njuguna; Godfrey M Bigogo; Beatrice Olack; John B Ochieng; Newton Wamola; Joel M Montgomery; John Williamson; Umesh D Parashar; Deron C Burton; Jacqueline E Tate; Daniel R Feikin
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

7.  Survival of HIV-1 vertically infected children.

Authors:  Mary-Ann Davies; Diana Gibb; Anna Turkova
Journal:  Curr Opin HIV AIDS       Date:  2016-09       Impact factor: 4.283

Review 8.  Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors.

Authors:  Daniel E Velasquez; Umesh Parashar; Baoming Jiang
Journal:  Expert Rev Vaccines       Date:  2017-12-29       Impact factor: 5.217

9.  Norovirus epidemiology in South African children <5 years hospitalised for diarrhoeal illness between 2009 and 2013.

Authors:  N A Page; M J Groome; S Nadan; R Netshikweta; K H Keddy; B Poonsamy; J Moyes; S Walaza; K Kahn; S A Madhi; M B Taylor; J Mans; C Cohen
Journal:  Epidemiol Infect       Date:  2017-04-10       Impact factor: 4.434

10.  Rotavirus surveillance in urban and rural areas of Niger, April 2010-March 2012.

Authors:  Anne-Laure Page; Viviane Jusot; Abdoul-Aziz Mamaty; Lagare Adamou; Jérôme Kaplon; Pierre Pothier; Ali Djibo; Mahamane L Manzo; Brahima Toure; Céline Langendorf; Jean-Marc Collard; Rebecca F Grais
Journal:  Emerg Infect Dis       Date:  2014-04       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.